The three supportive criteria are contiguous spinal cord MRI lesion extending over ≤3 vertebral segments, brain MRI not meeting the diagnostic criteria for multiple sclerosis (MS), and seropositive NMO-IgG. The diagnosis and prognosis of NMO are different from MS. Early aggressive treatment of NMO may be more efficient in preventing permanent neurologic deficit than early treatment of MS.

In most cases of acute neurologic deterioration with contiguous, intramedullary cervical spinal cord lesion, immediate surgical approach and decompression of the lesion are performed. However, when a sufficient and complete diagnosis of the lesion is made, as in our presenting case, decompressive operation can be avoided and achieve a better prognosis.

CASE REPORT

This 20-year-old woman had no other medical history. The patient had been suffering motor weakness in both upper extremities and radiating pain in both hands since 3 weeks ago. She experienced progression of pain, sensory changes, and lopsided motor weakness to the left side of the body. At the initial physical examination, a motor grade of both upper extremities was determined as grade 4 and no weakness was found in lower extremities. She was generally mildly hypertonic, although there was no Babinski sign or clonus. She complained of mild radiating pain in...
both hands, which was not one-sided with inexplicit dermatome. The patient underwent brain and whole spine MRI, which revealed a heterogeneously enhancing mass in the central posterior aspect of the spinal cord at the C1-6 level (Fig. 1). Brain MRI showed no specific findings. She was suspected of a tumorous condition, particularly ependymoma. Following this, she was admitted to our hospital for further evaluation of neurologic change. On the second hospital day, her motor function in both upper extremities suddenly deteriorated from grade 4 to 3. Cervical MRI was performed again, which revealed further extension of the hyperintense lesion on T2 weighted image and more intramedullary enhancing lesion on the T1 weighted image than that on the initial MRI image (Fig. 2). We hypothesized that the origin of neurologic deterioration was spinal cord compression by tumor bleeding. We immediately started intravenous steroid therapy and carried out total laminectomy C2-6 for decompression with surgical biopsy.

We performed C2-6 laminectomy and after opening the dura, the spinal cord was edematous but otherwise normal (Fig. 3). In the operation field, there was no tumor like lesion, discoloration or hypervascularization. We obtained frozen biopsy from a site near the lesion which was obtained consistent with astrocytic cell proliferation. Due to the gross normal finding and no tumorous frozen biopsy, we stopped the removal procedure of the mass lesion to prevent another potential spinal injury. The operation was closed by lateral mass screw fixation and fusion C2-6.

On the first postoperative day, her vital signs were stable, and suffered from nuchal pain, but her motor weakness remained the same. However, from the second postoperative day, motor weakness in both upper extremities became gradually better along with improvement of other sensory symptoms. On the twelfth postoperative day, permanent biopsy revealed abundant histiocytic collection, perivascular lymphocytic inflammation and reactive astrocytic proliferation. There was no evidence of a neoplastic process and no oligoclonal bands. The pathologist strongly suggested the diagnosis of neuromyelitis optica. Only then did we investigate her ophthalmic symptoms with a suspicion of another disease. She recalled her visual disturbance 5 years ago. Since then, there was no symptom until visit our department. We referred her to ophthalmology and revealed optic atrophy with disc pallor with optic neuritis on her left eye. Finally, her diagnosis was determined on NMO.

On the fourteenth postoperative day, her motor grade was improved to grade 5 and the patient could perform her daily tasks including eating food. We continued postoperative steroid treatment and started rehabilitation. After rehabilitation, she regained most of her upper-extremity motor functions and her ability to walk. Her pain significantly disappeared. When she
Fig. 4. Postoperative cervical MRI (after 3 months from surgery) shows improvement of cord swelling and remaining focal high signal foci on T2 weighted image. A : T1 weighted image. B : T2 weighted image. C : T1 weighted enhanced image.

was discharged from the hospital, there remained only mild nuchal pain. After 3 month from surgical intervention, her follow-up cervical MRI showed dramatic improvement (Fig. 4).

DISCUSSION

Many non-neoplastic lesions are misdiagnosis as intramedullary spinal cord tumors through radiographic findings and clinical symptoms. More specifically, the following misdiagnoses are made: infectious disorders (tuberculosis, fungal, bacterial), demyelination (MS), granulomatous disease, vascular lesions and syringomyelias.

It is difficult to distinguish these lesions from neoplastic spinal cord tumors from only case history and physical examination. In substance, we can get conclusive evidence through biopsy of the lesion, but it can be very invasive and cause irreversible neurologic injury. Thus, in our case, the overall comprehension of NMO was helpful to manage the patient who was likely to be misdiagnosed. A sound knowledge of the differential diagnosis between NMO and MS may also be of additional assistance.

In 1894, Devic described the clinical symptoms of NMO for the first time: optic neuritis and acute transverse myelitis. His patients had monophasic or relapsing courses of neuromyelitis optica. Improvements in biomarkers and immunoassay techniques gave rise to the revised definition of neuromyelitis optica.

The clinical presentation of optic neuritis relapse is more commonly unilateral than bilateral with ocular pain, and relapse of optic neuritis and myelitis usually appear gradually rather than rapidly. Most relapses worsen over the course of few days and then slowly improve after severe neurologic deterioration. The followings are typical symptoms of relapse: ocular pain with visual loss, myelitis with severe symmetric paralysis, sensory change below the lesion and bladder dysfunction.

We can typically see central scotoma, although other visual changes such as blindness, bitemporal hemianopsia are also detected by the visual field test in NMO patients.

The symptoms of transverse myelitis are para- or tetraparesis below the lesion, an almost symmetrical sensory change and sphincter dysfunction.

In our case, the patient’s NMO visual symptoms were not clear. Three months later, she said that had experienced visual blurring 3 years ago. She had normal motor power, no sensory deficit (even nuchal pain), and no visual symptoms.

Most patients with NMO have relapsing episodes of optic neuritis and myelitis, rather than a monophasic course. Relapse occurs within 1 year in 60% of patients and within 3 years in 90%. Improvements in biomarkers and immunoassay techniques have led to the revised definition of neuromyelitis optica.

At an early stage of NMO, spinal MRI may show typical patterns of NMO, such as snake-eye or owl-eye indicating spinal artery ischemia. In brain MRI, most lesions are non-specific. The localization of cord lesions in the axial plane has various diversities, but is predominantly centrally located in AQP-4 (aquaporin-4) antibody positive patients.

As NMO-IgG, Aquaporin-4 (AQP-4) antibody in the serum is directed against AQP-4, osmosis-driven, and bidirectional water channel expressed on the foot processes of astrocytes in the CNS. Positive for NMO-IgG/AQP4 antibodies secures credible evidence for the diagnosis of NMO (more than half the cases for NMO patients) and is a prognostic factor for high-risk disease. For treatment of NMO, we must bear in mind two mainpoints: one is to manage the inflammatory damage in acute sudden attacks and the other one is maintenance treatment to avoid relapses.

Risk factors of a poor prognosis are the number of relapses in the first 2 years of disease activity, the severity of the first attack and pre-existing autoimmune disorder. In studies of broad spectrum NMO related disorders, the 5-year survival rate of NMO was 68%. The most frequent cause of death is neurogenic respiratory failure. Luckily, our patient did not undergo relapsing episodes after the first attack and on her visual field revealed no central scotoma.

Spinal cord lesions contiguous over 3 vertebral levels are the most convincing findings for the diagnosis of NMO, and spinal cord lesions contiguous over 2 more vertebral segments are rarely found in MS. The localization of cord lesions in the axial plane has various diversities, but is predominantly centrally located in AQP-4 antibody positive patients.

At an early stage of NMO, spinal MRI may show typical patterns of NMO, such as snake-eye or owl-eye indicating spinal artery ischemia. In brain MRI, most lesions are non-specific and asymptomatic in NMO, except for optic nerve enhancement of optic neuritis. But, in MS, MRI findings of brain are mostly periventricular white-matter abnormal lesions.

As NMO-IgG, Aquaporin-4 (AQP-4) antibody in the serum is directed against AQP-4, osmosis-driven, and bidirectional water channel expressed on the foot processes of astrocytes in the CNS. Positive for NMO-IgG/AQP4 antibodies secures credible evidence for the diagnosis of NMO (more than half the cases for NMO patients) and is a prognostic factor for high-risk disease. For treatment of NMO, we must bear in mind two mainpoints: one is to manage the inflammatory damage in acute sudden attacks and the other one is maintenance treatment to avoid relapses. The first depends on high dose intravenous corticosteroids and immunossuppressants. Additionally, low AQP-4 antibody titers by immunosuppressant treatment can reduce the occurrence of relapses. Frequent relapsing
NMO attacks are related to permanent neurologic disability. Thus, it is momentous to commence treatment as early as possible to avoid new relapses and further disability.

The serum sample was referred by another research institute, but the titer was low and not specific for diagnosis. A diagnosis of non-neoplastic disease on cervical lesion must have underlying laboratory investigations and diagnostic procedures before invasive surgical intervention. However, by the surgeon’s inclination, surgery may be considered as an alternative choice of treatment, if the patient’s neurologic deficit is rapidly deteriorated. We should closely observe changes of the patient’s trivial symptoms and be aware of a minor possibility of rare diseases such as NMO that can cause catastrophic results. Intense studies regarding biomarkers and immunoassay techniques are required for noninvasive, cost-effective diagnosis.

CONCLUSION

A sudden motor deterioration with contiguous, intramedullary cervical spinal cord lesion could be misdiagnosed as a tumorous condition, but may actually be the symptoms of demyelinating diseases, such as MS and NMO. Early diagnosis and treatment of NMO determine the prognosis and sequelae of the disease. Thus, appropriate diagnosis results in suitable medical treatment (although it may require surgical approach), if careful attention is drawn to clinical clues, including visual symptoms and relapsing neurologic events. NMO must be included in the differential diagnosis of these lesions to rescue the patient from invasive surgical interventions. More specific diagnostic tools may be necessary for early diagnosis and proper treatment.

• Acknowledgements

This work was supported by Dankook University research fund in 2011.

References
1. Das A, Puvanendran K : A retrospective review of patients with clinically definite multiple sclerosis. Ann Acad Med Singapore 27 : 204-209, 1998
2. de Seze J, Blanc F, Jeanjean L, Zéphir H, Labauge P, Bouyon M, et al. : Optical coherence tomography in neuromyelitis optica. Arch Neurol 65 : 920-923, 2008
3. Downer JJ, Leite MI, Carter R, Palace J, Kuker W, Quaghebeur G : Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete? Neuroradiology 54 : 279-285, 2012
4. Ghezzi A, Bergamaschi R, Martinelli V, Trojano M, Tola MR, Merelli E, et al. : Clinical characteristics, course and prognosis of relapsing Devic’s Neuromyelitis Optica. J Neurol 251 : 47-52, 2004
5. Hui AC, Wong RS, Ma R, Kay R : Recurrent optic neuritis with multiple endocrinopathies and autoimmune disorders. J Neurol 249 : 784-785, 2002
6. Jarius S, About-Eine F, Waters P, Kuenz B, Hauser A, Berger T, et al. : Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131 (Pt 11) : 3072-3080, 2008
7. Kira J : Multiple sclerosis in the Japanese population. Lancet Neurol 2 : 117-127, 2003
8. Krampl A, About-Eine F, Jecel J, Lang W, Fertl E, Hruby W, et al. : Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur Radiol 19 : 2535-2543, 2009
9. Kuroiwa Y, Igata A, Itabara K, Koshijima S, Tsukabai T : Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1,084 cases. Neurology 25 : 845-851, 1975
10. Lee M, Epstein FI, Rezai AR, Zagzag D : Nonneoplastic intramedullary spinal cord lesions mimicking tumors. Neurosurgery 43 : 778-794; discussion 794-795, 1998
11. Lennon VA, Wingerchuk DM, Kryzer TJ, Pitttock SJ, Lucchinetti CF, Fujihara K, et al. : A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364 : 2106-2112, 2004
12. Mandell RN, Ahmed W, Dencoff JE : Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51 : 1219-1220, 1998
13. Matiello M, Lennon VA, Jacob A, Pitttock SJ, Lucchinetti CF, Wingerchuk DM, et al. : NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 70 : 2197-2200, 2008
14. Naismith RT, Tutlam NT, Xu J, Klawiter EC, Shepherd J, Trinkaus K, et al. : Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology 72 : 1077-1082, 2009
15. Nakamura M, Miyazawa I, Fujihara K, Nakashima I, Misu T, Watanabe S, et al. : Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol 255 : 163-170, 2008
16. Nishiyama S, Ito T, Misu T, Takahashi T, Kawasaki A, Suzuki N, et al. : A case of NMO serospositive for aquaporin-4 antibody more than 10 years before onset. Neurology 72 : 1960-1961, 2009
17. O’Riordan JJ, Gallagher HL, Thompson AJ, Howard RS, Kingsley DP, Thompson EI, et al. : Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatry 60 : 382-387, 1996
18. Pitttock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA : Neuromyelitis optica: brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63 : 964-968, 2006
19. Saiz A, Zuliani L, Bianco Y, Tavolato B, Giometto B, Graus F, et al. : Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol 254 : 1233-1237, 2007
20. Schwartz TH, McCormick PC : Non-neoplastic intramedullary pathology: Diagnostic dilemma: to Bx or not to Bx, J Neurooncol 47 : 283-292, 2000
21. Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. : EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17 : 1019-3102, 2010
22. Sellner J, Lüthi N, Bühler R, Gebhardt A, Findling O, Greive I, et al. : Acute partial transverse myelitis: risk factors for conversion to multiple sclerosis. Eur J Neurol 15 : 398-405, 2008
23. Vernant JC, Cabre P, Smadja D, Merle H, Caubarré I, Mikol J, et al. : Recurrent optic neuritis with endocrinopathies: a new syndrome. Neurology 48 : 58-64, 1997
24. Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, Fujihara K, et al. : Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 13 : 968-974, 2007
25. Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K, et al. : Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 13 : 128-132, 2007
26. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG : The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53 : 1107-1114, 1999
27. Wingerchuk DM, Lennon VA, Pitttock SJ, Lucchinetti CF, Weinshenker BG : Revised diagnostic criteria for neuromyelitis optica. Neurology 66 : 1485-1489, 2006
28. Wingerchuk DM, Weinshenker BG : Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 60 : 948-853, 2003